The call highlighted significant progress in expanding Symvess approvals and sales, including entering military markets, and successful clinical trial results. However, challenges included a denial of CMS NTAP application and delays caused by public attacks.

Company Guidance -

Q3 2025

During the Humacyte Second Quarter 2025 Results Conference Call, significant progress in the commercial launch of Symvess was highlighted, with VAC approvals expanding eligibility to 82 civilian hospitals, up from just 5 previously, and an additional 40 VAC sites under review. The company recorded a notable increase in sales, with July product sales reaching $0.3 million, surpassing total sales for the first half of the year. The U.S. Defense Logistics Agency granted ECAT listing approval, facilitating Symvess availability at approximately 35 military treatment facilities and 160 U.S. Department of Veterans Affairs hospitals. The call also addressed financial results, noting a second-quarter revenue of $0.3 million, with cost-reduction measures expected to yield over $50 million in savings through 2026. Research and development expenses decreased to $22.0 million for the quarter, with a net loss of $37.7 million, a substantial improvement from the previous year's $56.7 million loss. Cash reserves stood at $88.4 million as of June 30, 2025. Despite CMS declining the NTAP application for Symvess, the company remains optimistic about private payer reimbursement discussions, driven by promising clinical data. The call also provided updates on the ATEV program, with the V012 Phase III trial targeting completion of patient enrollment by year-end and a supplemental BLA filing anticipated in the second half of 2026.

Expansion of Symvess Approvals

The number of civilian hospitals eligible to purchase Symvess increased from 5 to 82, and an additional 40 VAC sites are currently reviewing the product.

First Military Sale and ECAT Listing

Recorded the first sale to a U.S. military facility and received ECAT listing approval, making Symvess available to 35 military treatment facilities and 160 VA hospitals.

V007 Phase III Trial Success

Presented successful results from the V007 Phase III trial at the Society of Vascular Surgery Annual Meeting, showing significant improvements in patency and usability.

Sales Surge in July

July product sales of approximately $0.3 million exceeded total sales for the first half of the year.

Significant Cost Reductions

Implemented a plan to reduce workforce and costs, estimating savings up to $38 million in 2026.

Humacyte (HUMA) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

HUMA Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Nov 07, 2025	2025 (Q3)	-0.16 / -	-0.33	―	―	―
Aug 11, 2025	2025 (Q2)	-0.16 / -0.24	-0.48	50.00% (+0.24)	―
May 13, 2025	2025 (Q1)	-0.19 / 0.28	-0.29	196.55% (+0.57)	―
Mar 28, 2025	2024 (Q4)	-0.25 / -0.16	-0.24	33.33% (+0.08)	―
Nov 08, 2024	2024 (Q3)	-0.25 / -0.33	-0.25	-32.00% (-0.08)	―
Aug 13, 2024	2024 (Q2)	-0.24 / -0.48	-0.22	-118.18% (-0.26)	―
May 10, 2024	2024 (Q1)	-0.23 / -0.29	-0.36	19.44% (+0.07)	―
Mar 22, 2024	2023 (Q4)	-0.24 / -0.24	-0.04	-500.00% (-0.20)	―
Nov 09, 2023	2023 (Q3)	-0.25 / -0.25	-0.25	0.00% (0.00)	―
Aug 14, 2023	2023 (Q2)	-0.22 / -0.22	0.35	-162.86% (-0.57)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

HUMA Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 11, 2025	$2.48	$1.74	-29.84%
May 13, 2025	$1.32	$1.73	+31.06%
Mar 28, 2025	$2.01	$1.96	-2.49%
Nov 08, 2024	$5.26	$5.78	+9.89%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Humacyte (HUMA) report earnings?

Humacyte (HUMA) is schdueled to report earning on Nov 07, 2025, Before Open (Confirmed).

What is Humacyte (HUMA) earnings time?

Humacyte (HUMA) earnings time is at Nov 07, 2025, Before Open (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is HUMA EPS forecast?

HUMA EPS forecast for the fiscal quarter 2025 (Q3) is -0.16.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing